DRUG:AU:AU-BetaShares Global Healthcare Currency Hedged (AUD)

ETF | Others |

Last Closing

USD 8.26

Change

+0.02 (+0.24)%

Market Cap

USD 0.17B

Volume

0.04M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-17 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
VAS:AU Vanguard Australian Shares

+0.84 (+0.87%)

USD 17.87B
IVV:AU iShares Core S&P 500 AUD

+0.14 (+0.24%)

USD 11.60B
VGS:AU Vanguard MSCI International Sh..

+0.53 (+0.39%)

USD 10.39B
QUAL:AU VanEck Vectors MSCI World ex A..

+0.13 (+0.23%)

USD 7.35B
IOZ:AU Ishares Core S&P/Asx 200

+0.25 (+0.79%)

USD 6.40B
STW:AU SPDR® S&P/ASX 200 Fund

+0.54 (+0.76%)

USD 5.57B
VTS:AU Vanguard US Total Market Share..

+1.39 (+0.32%)

USD 5.54B
NDQ:AU Betashares Nasdaq 100

+0.15 (+0.33%)

USD 5.22B
HNDQ:AU BetaShares NASDAQ 100 ETF - Cu..

+0.31 (+0.79%)

USD 4.86B
A200:AU BetaShares Australia 200

+1.12 (+0.86%)

USD 4.72B

ETFs Containing DRUG:AU

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.09% 89% A- 73% C
Dividend Return 0.35% 11% F 7% C-
Total Return 5.44% 89% A- 73% C
Trailing 12 Months  
Capital Gain -3.39% 12% F 51% F
Dividend Return 2.93% 41% F 33% F
Total Return -0.46% 11% F 50% F
Trailing 5 Years  
Capital Gain 54.39% 62% D 66% D+
Dividend Return 13.68% 29% F 23% F
Total Return 68.07% 49% F 63% D
Average Annual (5 Year Horizon)  
Capital Gain 6.67% 64% D 54% F
Dividend Return 8.45% 62% D 53% F
Total Return 1.78% 57% F 37% F
Risk Return Profile  
Volatility (Standard Deviation) 8.52% 64% D 92% A
Risk Adjusted Return 99.21% 88% B+ 95% A
Market Capitalization 0.17B 33% F 65% D

Annual Financials (AUD)

Quarterly Financials (AUD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.